Most Recent
Lundbeck wins appeal in decade-long IP battle with Sandoz over Lexapro
Intellectual Property 2024-09-20 11:30 pm By Christine Caulfield

Pharmaceuticals giant Lundbeck has succeeded in overturning IP Australia’s decision granting Novartis unit Sandoz a licence to sell a generic version of top-selling antidepressant Lexapro.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Firm’s contingency fee re-do wins over judge in class actions against banks
Class Actions 2023-03-03 5:50 pm By Cindy Cameronne

A law firm has won its second bid for a group costs order in three class actions against banks over flexible commission schemes after a judge in 2021 rejected what was then the first-ever application for a contingency fee.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

After GetSwift, judge could not hear split trial in Revlimid patent case, court told
Intellectual Property 2021-07-20 8:39 pm By Christine Caulfield

A proposal by Bristol-Myers Squibb-owned Celgene to split a second trial into two more hearings in a dispute over patents covering the pharmaceutical maker’s top selling cancer drug Revlimid would result in wasted costs, wasted time and require a second judge, a court has been told.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?